AFP and hepatocellular carcinoma: Clinical cohort analysis revealed that GGT‐II had a sensitivity of 78.7% and a specificity of 92.3% (AUC = 0.89) for the diagnosis of HCC and was superior to AFP (AUC = 0.67) in early stage disease and that hepatocellular carcinoma‐specific gamma‐glutamyltransferase isoform II (GGT‐II) is considered to be the best hepatocellular carcinoma biomarker, with the exception of alpha fetoprotein (AFP) [135] (Table 5).